1/字_筆_英譯中_論文_5000字_20101123 - 翻譯

──────────────────────────────────────
[必]工作類型：（筆譯／口譯）皆可
[必]涉及語言：英中
[必]所屬領域：牙醫/骨在生
[必]工作性質：翻譯
──────────────────────────────────────
[必]工 作 量：（字數／頁數／小時數／天數）(5000/10/)
[必]工作難度：專業名詞
[必]工作要求：翻譯看得懂全文
[必]截 稿 日：20101123
[必]工作報酬：（若請譯者報價，必須載明預算上限）
──────────────────────────────────────
[必]應徵條件：有牙醫背景或是知道骨頭在生
[必]應徵期限：11/23
[必]聯絡方式：站內信
──────────────────────────────────────
[選]參考段落：NON-CERAMIC ALLOPLASTIC IMPLANT MATERIALS
Although most syntheiic materials currently used to treat periodontal
defects are calcium phosphate ceramic com- pounds (tricalcium phosphate,
porous hydroxyapatite, non- porous hydroxyapatite or combinations of
hydroxyapatite and tricalcium phosphate [biphasic calcium phosphate]), a
number of non-ceramic synthetic materials have also been used in recent
years. These include materials such as cal- cium sulfate (plaster of paris)
which is readily available, inexpensive, easy to handle, and sterilizable.
Although it has been shown to be biocompatible and readily absorbed, there is
no evidence that it has any osteoinductive proper- ties (Shaffer and App,
1971).
另一篇
Quattlebaum et al. (1988) investigated the antigenicity of FDBA in human
periodontal osseous defects and could not detect anti-HLA antibodies in any
of the 20 patients at any time. However, the authors also noted that it is
possible that the amount of FDBA used during routine periodontal grafting
procedures provides an insufficient antigenic chal- lenge to the patient.
The safety of FDBA was shown by Mellonig et al. (1992) who evaluated
HIV-spiked human cortical bone and bone obtained from an AIDS patient. The
bone was tested for the presence of HIV both before and after processing. The
acid decalcification process and use of vimcidal agents destroyed the HIV,
thus showing the safety of DFDBA. Only 2 cases of HIV transmission from
grafting have been known to occur and both were with unprocessed fresh or
frozen bone allografts.

[選]試 譯 文：（若未提供請勿刪除）
──────────────────────────────────────
[選]其他事項：（若未提供請勿刪除）
──────────────────────────────────────

--